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Ferritin family proteins and their use
in bionanotechnology
Didi He and Jon Marles-Wright
Institute of Structural and Molecular Biology, School of Biological Sciences, University of Edinburgh, Mayfield Road, Edinburgh EH9 3JR, United Kingdom
Ferritin family proteins are found in all kingdoms of life and act to store iron within a protein cage and to
protect the cell from oxidative damage caused by the Fenton reaction. The structural and biochemical
features of the ferritins have been widely exploited in bionanotechnology applications: from the
production of metal nanoparticles; as templates for semi-conductor production; and as scaffolds for
vaccine design and drug delivery. In this review we first discuss the structural properties of the main
ferritin family proteins, and describe how their organisation specifies their functions. Second, we
describe materials science applications of ferritins that rely on their ability to sequester metal within
their cavities. Finally, we explore the use of ferritin as a container for drug delivery and as a scaffold for
the production of vaccines.
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Nanotechnology concerns itself with materials in the 1–100 nm
size range; at this scale materials exhibit remarkably different
properties to bulk materials. Graphite is the most common natu-
rally occurring allotrope of carbon and has been used by humans
for over 500 years, yet in single layers it is the 21st century wonder-
material graphene [1]. In bionanotechology, biological systems as
varied as viruses, protein complexes, lipid vesicles and artificialCorresponding author: Marles-Wright, J. (Jon.marles-wright@ed.ac.uk)
http://dx.doi.org/10.1016/j.nbt.2014.12.006 
1871-6784/ 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY liccells, are being developed for applications in civil engineering,
medicine and materials science [2,3]. The capsids of viruses and
other protein complexes, such as ferritins and heat shock proteins,
with defined interior cavities are particularly attractive targets for
bionanotechnology: they are readily produced in large quantities;
have well-characterised atomic structures; are usually monodis-
perse in solution; and are amenable to chemical and biological
modification [4,5].
The ferritin family proteins are ubiquitous in nature and have
been the subject of much research focused on their applications inwww.elsevier.com/locate/nbt
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eviewbionanotechnology. Almost 3000 published patents mention
ferritin and nanotechnology, 100 of which specifically mention
bionanotechnology. The primary role of ferritin is to protect cells
from the damage caused by the Fenton reaction; where, in oxidis-
ing conditions, free Fe(II) produces harmful reactive oxygen spe-
cies that can damage the cellular machinery [6]. Ferritins are also
able to store a significant quantity of iron within a hollow core,
and act as storage systems for iron within cells [7].
The active site of ferritin family proteins, named the ferroxidase
centre (FOC), is able to safely oxidise iron (II) in the presence of
oxygen, or peroxide, to produce ferrihydride minerals that are
stored within the core of the ferritin nanocage [8]. The FOC active
site has conserved glutamic acid, aspartic acid and histidine resi-
dues that coordinate iron and facilitate its controlled oxidation [9].
Because ferritin family proteins are able to mineralise and store
metal ions, they have been the focus of much research for the
production of metal nanoparticles [10,11], and as templates for
semi-conductor production [12].
The ferritin cage itself is highly symmetrical, and is made up of
24 subunits arranged in an octahedral (432) symmetry. The ferritin
cage displays remarkable thermal and chemical stability and it
is particularly amenable to reconstitution through controlled
(dis-)assembly [13]; it is also possible to modify the surface of
the ferritin cage through the addition of peptide and protein tags
[14]. These characteristics have made ferritins attractive vectors for
the delivery of drug molecules [15] and as scaffolds for vaccine
design [16]. In Table 1 we summarise the bionanotechnology
applications of ferritin covered in this review, and highlight the
source of the ferritin and features of the protein that are exploited
in each application. In this review we will explore how the
structural and functional features of ferritin nanocages have been
applied in materials science to make use of their natural ability to
sequester metal; and in the biomedical field, where modified
ferritin proteins are used as drug delivery vehicles, and as scaffolds
for vaccine development. Each application will be put into contextTABLE 1
Applications and sources of ferritin used in bionanotechnology
Application Core composition 
MRI contrast agent Iron oxyhydroxide 
Iron oxyhydroxide 
Phosphate removal from water Ferric phosphate 
Quantum label ZnSe 
Semi-conductor template CdS/ZnSe 
Antibacterial silver nanoparticles Ag 
Gold nanoparticles Au 
Drug delivery Doxorubicin–Cu(II) complex 
Information storage CoPt 
Magnetic nanoparticles Co3O4
Vaccine development None 
Chemical catalyst Pt 
Pd 
Cu 
Au 
TiO2
652 www.elsevier.com/locate/nbtand considered in contrast to alternative methods to reach the
same ends. Finally, we will consider the scope for commercialising
and exploiting the inventions highlighted in this review.
Ferritin family proteins
Before summarising the applications of the ferritin family proteins
we must introduce the various family members and highlight their
structural and functional differences. The classic ferritin (Ftn),
found in eukaryotes and some bacteria, is a four-helix bundle
protein of around 200 amino acids that forms a cage of 24 subunits
arranged in octahedral 432 symmetry [17], with an outer diameter
of roughly 12 nm and an inner diameter of 8 nm (Fig. 1a). Mam-
malian ferritins are heteropolymers consisting of an H-chain
subunit (182 amino acids, containing the ferroxidase centre)
and an L-chain subunit (174 amino acids, facilitating the miner-
alisation of Fe3+) [18]. Other Ftn variants exist including the
amphibian M-chain ferritin, which has the FOC active site, but
is shorter than H-chain Ftn [9]
Along with the classic ferritin, some bacteria and archaea pos-
sess bacterioferritin (Bfr), which differs from Ftn by the incorpo-
ration of twelve b-type haem groups between subunits in a twofold
symmetric binding site [19] (Fig. 1a). The role of the haem group is
not completely clear, although recent work has shown that it may
act to allow electron transport from Bfr-associated ferredoxins to
the Bfr core to mobilise stored iron [20]. The Bfr-associated ferre-
doxins possess a [2Fe-2S] cluster that is positioned above the haem
group when the protein binds to Bfr, this molecular-wire allows
electrons to be passed from cofactors, such as NAD(P)H, to the iron
core to reduce the mineralised iron [20].
The mini-ferritin, DNA-binding Protein from Starved cells
(DPS), was initially discovered in Escherichia coli cells during
the stationary phase and is found in many bacteria and some
archaea [21,22], and its primary role is to protect the bacterial
chromosome from oxidative damage [25]. In contrast to the
24-meric assembly of Ftn and Bfr it has a distinct dodecamericSource Reference
Transfected human H-chain ferritin [38]
Adenovirus/lentivirus vector [47]
Pyrococcus furiosus ferritin [28]
Horse spleen apoferritin [59]
Apoferritin [60]
Pyrococcus furiosus ferritin [37]
Engineered human H-chain ferritin [35]
Engineered human H-chain ferritin [35]
Surface-modified human H-chain ferritin [15]
Horse spleen apoferritin [67]
Pyrococcus furiosus ferritin [33]
Horse spleen apoferritin [68]
Helicobacter pylori non-heam ferritin [61]
Apoferritin from Sigma [69]
Recombinant L-chain apoferritin from horse liver [36]
Horse spleen apoferritin [70]
Horse spleen apoferritin [31]
Mammalian apoferritin [38]
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FIGURE 1
Structure of ferritin family protein nanocages. The quaternary structures of the three ferritin family protein nanocages are shown as cartoon representations, a
single monomer is coloured grey and bound iron ions in ferroxidase active sites are shown as orange spheres. (a) Structure of ferritin from Pseudonitzchia
multiseries (PDB ID: 4IWJ) [17]. Grey lines and polygons depict the relationship between the symmetry axes of the ferritin cage: 2-fold, ellipse; 3-fold, triangle; 4-fold,
square. (b) Structure of bacterioferritin from Desulfovibrio desulfuricans (PDB ID: 1NF4) [71]. The bound haem-b co-factors are shown as yellow sticks between the
protein monomers; due to the co-ordination of this group the 2-fold axes between monomers are not true symmetry axes. Bacterioferritin is shown in the same
orientation as ferritin. (c) Structure of DPS from Microbacterium arborescens (PDB ID: 2YJK) [22]. DPS is a dodecamer and has 2- and 3-fold symmetry axes; the
relationship between these is illustrated with grey lines and a triangle and ellipse.
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wassembly, with 9 nm outer and 5 nm inner diameters (Fig. 1c). Like
Ftn and Bfr, DPS has a ferroxidase site and can store iron within its
core, albeit in smaller quantities due to the smaller inner diameter
of the dodecameric complex [23,24]. DPS expression is induced
during stationary phase and it binds to the bacterial chromosome
in a sequence-independent manner through interactions mediat-
ed by positively charged N-terminal tails. Furthermore, the com-
plex self-associates to induce chromosome condensation [26].
Knockout of DPS genes in pathogens, such as Bacillus anthracis,
reduces tolerance to oxidative stress and thus their virulence [27].
Production of ferritin for bionanotechnology
applications
The various nanotechnology applications of ferritin covered in
this review use ferritin from a number of sources and in most cases
only relatively small quantities of protein are used in these proof
of concept projects. Very few industrial-scale processes use ferri-
tin-based technologies, with the use of Pyrococcus furiosus ferritin
in water treatment the most notable [28]. Ferritin family proteins
are found in all kingdoms of life and as such are relatively easy to
isolate and produce [29]. Horse spleen ferritin is available for
roughly £200 a gram from major chemical suppliers, while human
ferritin variants are more expensive at around £50 per microgram
(prices taken from Sigma–Aldrich website, November 2014).
Recombinantly produced bacterial and archaeal ferritin nano-
cages are readily produced at the milligram to gram scale in the
laboratory (references in Table 1). It is possible to produce mam-
malian ferritin variants by recombinant methods, although the
subunit composition varies from the native protein as the latter
contains L- and H-chain variants in variable ratios, while the
former are usually produced as just the active site containing
H-chain variant [30].Purification of recombinant ferritin and DPS nanocages is facile
because these proteins are generally thermostable. Established
protocols separate recombinantly produced ferritin by heating
clarified E. coli cell lysate to around 708C to denature the native
E. coli proteins and leave only the thermostable ferritin in solution
(references in Table 1). The denatured proteins are removed by
centrifugation and the ferritin remains in the supernatant. Further
purification steps, such as chromatographic separations and dif-
ferential centrifugation, may be performed to produce material
with very high purity. Both native and recombinant ferritin often
contains a significant amount of iron within its mineral core, and
depending on the final application this may not be desired. The
iron core can be removed by reducing the iron with suitable
reducing and chelating agents, such as sodium dithionite and
EDTA, or BIPY [31].
Ferritin as a biomineralisation scaffold
The ferritin family proteins are probably the best-studied biomi-
neralisation scaffolds and are able to accommodate up to 4500 iron
atoms in a ferrihydride form within the central cavity [32]. In the
catalytic cycle of ferritin family proteins iron(II) is oxidised within
the ferroxidase centre; the resulting iron (III) ions transfer to the
central cavity and mineralise as Iron (III) hydrides where they form
microcrystals [29,33]. Negatively charged pores in the ferritin
shell, formed between subunits, allow the entry and exit of cations
during mineralisation and demineralisation [34]. The selectivity of
these channels is relatively broad and it is possible in vitro to induce
the mineralisation of a variety of metal ions, with a strong prefer-
ence for divalent cations [23], although ferritin will tolerate some
mono- and trivalent metal ions [35]. In practice, the ferritin cage
has been employed as a template to mineralise a range of different
non-physiological metals and metal complexes through eitherwww.elsevier.com/locate/nbt 653
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redox reactions, or photochemistry [5,36–38]. The conditions
required for the production of various metal nanoparticle cores
is summarised in Yoshimura’s excellent review [10].
Early studies on the plasticity of ferritin mineralisation demon-
strated the production of iron sulphide, Mn(III) oxide and mag-
netite (Fe3O4) cores [11]. The latter, ‘magnetoferritin’, has
potential uses as a magnetic contrast agent for cell imaging and
for the magnetic separation of labelled cells and particles [39].
Recent interest in the use of magnetoferritin has focused on using
it as a label to target and visualise tumour cells [40]. The negatively
charged interior and exterior surface of ferritin readily coordinates
metal ions, although the case of gold ions the efficiency of miner-
alisation is reduced by these surface interactions. To get around
this limitation reconstitution and washing of the ferritin cage has
been used to optimise the production of gold nanoparticles [31].
Surface modification by mutagenesis has allowed the production
of noble metal nanoparticles within the ferritin interior [32]. Co-
crystallisation of metals and semi-conducting compounds has also
been explored [12].
The range of possible metal nanoparticles that can be produced
within the ferritin cage is remarkable and it is clear from the
literature that careful experimental design and handling of the
protein is key to the success of the deposition of ions within
ferritin nanocages. Ferritin encapsulated metal nanoparticles
can be liberated by removal of the ferritin cage by chemical or
thermal means to leave highly homogeneous metal nanoparticles
with uses ranging from the production of ordered semi-conductor
arrays [10], quantum dots [41], and as anti-bacterial nanoparticles
[42]. The use of mineralised ferritin in nanodevice fabrication and
medical applications is discussed in more detail below.
The ability of ferritin to sequester phosphate within its core
along with iron is well documented [43,44] and this can occur
either simultaneously with iron sequestration, or after initial core
formation [28]. This phenomenon has been applied to the removal
of phosphate from water [28], where the P. furiosus ferritin has
been developed as an industrial-scale solution to prevent water
pollution and biofouling due to the phosphate content of seawater
and industrial waste streams (www.biaqua.com). Current phos-
phate removal systems rely on the precipitation of phosphate
using calcium and aluminium sulphates, or biological means
where bacteria are used to sequester and adsorb calcium [45].
These chemical and biological methods have high maintenance
costs, whereas the ferritin-based solution has a high capacity for
phosphate binding, is highly stable because it is isolated from a
thermophilic microorganism, and can be readily recycled [28]. The
range of potential uses for this system is huge, but it remains to be
seen whether it is widely adopted as an economical solution to
phosphate removal and water treatment.
Ferritin nanodevices
Both Ferritin and DPS have been used as scaffolds for the fabrica-
tion of inorganic nanodevices, such as quantum dots and nano-
wires [3,10,12]. In these applications, ferritin cages loaded with
mineral cores are deposited on silicon substrates that can be
silanized and functionalised with small molecules, or peptides.
The protein cage can be retained, or ablated with heat to leave the
core in place. Patterned semi-conductor cores deposited on silicon654 www.elsevier.com/locate/nbtwafers in this way have been used as memory gates [46,47].
Isolated metal cores have also been used as catalysts to seed the
growth of carbon nano-tubes and nanowires [48]. These examples
of the use of ferritins in the production of nanodevices are all at the
proof of concept stage for technology development. It remains to
be seen whether it will be possible to scale-up their production and
implement ferritins in industrial applications at significant scale to
have economic advantages over conventional semi-conductor
fabrication methods.
Ferritin based contrast agents for medical imaging
The plasticity of the in vitro mineralisation of ferritin makes it an
ideal tool for cellular imaging, as labelled heavy atoms and heavy
atom complexes can be readily sequestered within its core. Fur-
thermore, the ability to modify ferritin through protein engineer-
ing and chemical means has enabled their use as contrast agents in
basic scientific investigations of cellular ultrastructure and for
medical imaging. Iron-loaded ferritin has also been used as a
contrast agent in both electron microscopy [49] and MRI
[50,51]. We will discuss applications of ferritin in these imaging
modalities below.
Electron cryotomography (Cryo-ET) has become a valuable tool
for studying the ultrastructure of cells and tissues as it allows them to
be imaged at nanometre resolution in a near-native frozen-hydrated
state. The low contrast of images produced by this method means
that the identification of structures of interest is often challenging,
therefore ferritin has been proposed as an electron-dense label for
cryotomography. Ferritin fulfils the key requirement of a good
cellular label as it has a significantly higher contrast than the cellular
background due to the electron scattering properties of the iron
core, and the ferritin cage is well ordered and homogeneous. Fur-
thermore, surface modification of ferritin with fluorescent reporters,
enables correlative fluorescence microscopy/Cryo-ET [49]. Using a
multi-valent system like ferritin may produce sub-cellular artefacts
when studying protein-protein interactions, especially at the cell
surface, therefore care must be taken to control for the possibility of
introducing this type of artefact. Because of its distinctive and
highly homogeneous structure apo-ferritin has also been used as
a standard for estimating the magnification of micrographs in Cryo-
electron microscopy [52].
Magnetic Resonance Imaging (MRI) is a powerful diagnostic
tool in both clinical and research settings, and is non-invasive and
highly sensitive, with a resolution of up to 50 mm [53]. The most
common MRI modality relies on the detection of 1H, which is
abundant in tissues and gives a high quality signal that is positively
influenced by the chemical environment of the atom. Exogeneous
contrast agents are often used in conjunction with 1H to give
additional information and to label specific tissues and track
metabolic processes. Iron oxides and hydroxides, as found in
the ferritin core, are efficient contrast agents due to their super-
paramagnetic properties and the dark contrast they give in MRI
images [50].
The use of iron containing ferritin as an MRI contrast agent has
been explored using lentiviral and adenovirus vectors encoding
ferritin to transfect nerve cells in mice [51]. The transfected vectors
produce ferritin within the targeted cells, which then accumulate
excess iron because of the additional ferritin within them. This
initial study highlights the importance of considering the delivery
New Biotechnology Volume 32, Number 6 December 2015 REVIEW
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wvehicle for ferritin and nanoparticles, as the results showed that
the viral vectors themselves give enhanced MRI contrast due to the
immune response against them at injection sites. Furthermore,
due to the small size of ferritin, the authors note limited contrast
against background signal in vivo.
Alternative strategies to the viral-vector induced expression of
ferritin have been proposed that use recombinant ferritin tagged
with targeting peptides and loaded with elements that give higher
MRI contrast than iron, such as gadolinium [14]. Endothelial
tumour cells were visualised by this strategy using gadolinium-
loaded ferritin tagged with a peptide epitope specific for the neural
cell adhesion molecule that is expressed on the tumour cells, but
not healthy endothelial cells [54]. This approach gave a statisti-
cally significant enhancement to the MRI contrast localised spe-
cifically to the tumour cells. These studies highlight the promise of
the use of ferritin as an MRI contrast agent if problems associated
with the limited contrast available from native ferritin can be
addressed. The production of labelled ferritin nanocages through
the application of synthetic biology techniques for protein engi-
neering will broaden the potential applications of this versatile
scaffold.
Drug delivery via the ferritin cavity
Further to the use of ferritin as an MRI contrast agent, other
clinical applications for ferritin family proteins arise from their
nature as highly stable compartments that are biocompatible,
amenable to disassembly, reconstitution and surface modification.
These properties have been used to develop ferritin as a drug
delivery platform [15]. At physiological pH ferritin exists as a
stable 24-mer, whilst in highly acidic or basic solutions it disas-
sembles, and when returned to a neutral solution the complex
spontaneously reassembles. This phenomenon can be used to trap
molecules in solution within its cavity by dis/assembling ferritin in
the presence of drug solutions. This property has been used to load
the cavity with metal containing drugs, such as the cancer drug
cisplatin, and the iron chelator desferrioxamine B [55,56], these
drugs are readily encapsulated by ferritin due its natural tendency
to bind to metals.
The incorporation of non-metal-containing drugs within ferri-
tin is challenging due to the limited interactions between them
and the ferritin shell, and the diffusion of these molecules through
the surface pores. Strategies to overcome these problems have
focused on complexing drugs with transition metals, such as
Cu(II), prior to their internalisation [4], or the addition of charged
accessory molecules such as poly-L-aspartic acid to optimise load-
ing of ferritin with drugs [57]. By combining the loading of ferritin
with drugs and surface modification with peptide epitopes and
labels, ferritin can be specifically targeted to particular cell types
and tumours for efficient delivery of therapeutic agents. There are
limitations to the nature of the peptide labels and drugs that can be
added to ferritin that limit the range of targeting molecules that
can be used, but other protein-based nanocages have been dem-
onstrated as alternative drug-delivery platforms [58]. The number
of chemical processes involved in producing such delivery vectors
may make such systems economically unviable, but where highly
specific systems for the targeting of tumours are needed, ferritin
and other protein nanocages show a great deal of promise that will
hopefully transfer to a clinical setting.Ferritin nanoparticle vaccines
The role of nanotechnology in vaccine development is well estab-
lished [59], as is the use of viruses for the display of heterologous
proteins [2,60]. The highly symmetric and self-assembling ferritin
nanocage presents an attractive target for vaccine development. In
an elegant demonstration of the use of ferritin for vaccine devel-
opment, Kanekiyo and colleagues fused the influenza virus hae-
magglutinin (HA) to the surface of Helicobacter pylori ferritin [16].
Fusions of entire protein domains to the surface of ferritin are
complicated by the requirement to match the subunit organisa-
tion of the protein to be displayed on its surface with the inherent
symmetry of the ferritin cage itself. HA forms trimers with 30 A˚
between the central axes of each subunit, this matches the dis-
tance between the N-terminal residues of the H. pylori ferritin
structure, which are found at the 3-fold symmetry axis of the
ferritin cage. Immunisation of mice with the HA-Ftn nanoparticle
vaccine elicited the production of broadly neutralising antibodies
against different HA variants and showed enhanced potency com-
pared to a commercially available influenza vaccine, with no
autoimmune reaction due to the use of the H. pylori ferritin whose
sequence is highly divergent from human ferritin and which
incorporates limited quantities of iron when produced heterolo-
gously [61]. This study highlights the potential benefits of pro-
ducing and implementing synthetic nanoparticle vaccines, but a
degree of caution is required to avoid autoimmune reactions
caused by the vector itself. The use of such vaccines would abro-
gate the need to generate live viruses in cell-culture, and when
coupled with synthetic biology methods would allow multi-com-
ponent vaccines with broad activities to be produced entirely
recombinantly [62].
Future prospects
Medical imaging shows the greatest immediate prospects for wide-
spread adoption of the bionanotechnology applications of ferritin
presented in this review. The use of ferritin derivatives has poten-
tial to transform the diagnosis and treatment of tumours in situ. A
key limitation of this application is the poor MRI contrast achieved
by the native iron containing ferritin [51]; recent research on a
family of protein nanocompartments known as encapsulins has
identified a new class of ferritin-like proteins that are selectively
enclosed within the encapsulin shell, which is much larger than
the classical ferritin and may present a solution to this contrast
problem [63,64]. McHugh and colleagues propose that the encap-
sulins function as an iron mega-store as their internal cavities can
accommodate up to 10 times more mineralised iron than ferritin
[64]. It is in fact possible to sequester ferritin within an encapsulin
shell [65] and while this has been demonstrated in a recombinant
system it is not clear whether this is a physiologically relevant
arrangement. The compartmentalisation of EncFtn (encapsulated
Ftn) within the encapsulin shell is mediated by short C-terminal
localisation sequences, which can be appended to heterologous
proteins to direct them to the encapsulin interior [66]. This feature
of encapsulins makes them highly attractive platforms for exploi-
tation as cell factories, or to protect unstable protein cargoes.
In this review we have shown a range of technologies that
exploit the features of ferritin and ferritin family proteins and
have given examples drawn from current research that are explor-
ing ways to make use the unique properties of ferritins. The use ofwww.elsevier.com/locate/nbt 655
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phosphate is the only process-scale use of ferritin nanocompart-
ments to date; while the other examples presented are still at the
stage of laboratory-scale technology demonstrations [28]. The
question of whether ferritin-based semi-conductor and medical
systems will be used outside of the research laboratory rests on
economic factors relating to the cost of implementing these
technologies over the current state-of-the art in these fields. The
recent discovery of encapsulated ferritins and their protein con-
tainers has identified an exciting new platform for use in biona-
notechnology; the use of synthetic biology tools will enable their656 www.elsevier.com/locate/nbtrapid implementation in materials science, biotechnology, and
medical applications.
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